(-)-Oleocanthal exerts anti-melanoma activities and inhibits STAT3 signaling pathway

Oncology Reports

Volumn 37, Issue 1, 2017, Pages 483-491

  Gu, Yanli ^a   Wang, Jing ^a   Peng, Lixin ^a  

^a Daqing Oilfield General Hospital   (China)

Author keywords

( ) oleocanthal; Growth; Melanoma; Metastasis; Signal transducer and activator of transcription 3

Indexed keywords

CASPASE 3; CASPASE 9; GELATINASE A; GELATINASE B; OLEOCANTHAL; PHENOL DERIVATIVE; PROTEIN BCL XL; PROTEIN MCL 1; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ALDEHYDE; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BCL XL GENE; CANCER INHIBITION; CELL MIGRATION; CELL NUCLEUS; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MCL 1 GENE; MELANOMA; MELANOMA CELL LINE; METASTASIS INHIBITION; MMP 2 GENE; MMP 9 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR INVASION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; VEGF GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL CULTURE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; VASCULARIZATION;

ALDEHYDES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHENOLS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85006511367     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.5270     Document Type: Article

References (41)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL and Chanmugam A: Cutaneous malignant melanoma. Mayo Clin Proc 81: 500-507, 2006.
3. Chi Z, Li S, Sheng X, Si L, Cui C, Han M and Guo J: Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases. BMC Cancer 11: 85, 2011.
4. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365, 2012.
5. Callahan MK, Postow MA and Wolchok JD: Immunomodulatory therapy for melanoma: Ipilimumab and beyond. Clin Dermatol 31: 191-199, 2013.
6. Poust JC, Woolery JE and Green MR: Management of toxicities associated with high-dose interleukin-2 and biochemotherapy. Anticancer Drugs 24: 1-13, 2013.
7. Lopez-Bergami P, Fitchman B and Ronai Z: Understanding signaling cascades in melanoma. Photochem Photobiol 84: 289-306, 2008.
8. Kortylewski M, Jove R and Yu H: Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 24: 315-327, 2005.
9. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66: 3188-3196, 2006.
10. Messina JL, Yu H, Riker AI, Munster PN, Jove RL and Daud AI: Activated stat-3 in melanoma. Cancer control 15: 196-201, 2008.
11. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
12. Liu L, Nam S, Tian Y, Yang F, Wu J, Wang Y, Scuto A, Polychronopoulos P, Magiatis P, Skaltsounis L, et al: 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res 71: 3972-3979, 2011.
13. Liu L, Kritsanida M, Magiatis P, Gaboriaud N, Wang Y, Wu J, Buettner R, Yang F, Nam S, Skaltsounis L, et al: A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling. Cancer Biol Ther 13: 1255-1261, 2012.
14. Kamran MZ and Gude RP: Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway. Biomed Pharmacother 67: 399-405, 2013.
15. Martínez ME, Marshall JR and Giovannucci E: Diet and cancer prevention: The roles of observation and experimentation. Nat Rev Cancer 8: 694-703, 2008.
16. Tong LX and Young LC: Nutrition: The future of melanoma prevention? J Am Acad Dermatol 71: 151-160, 2014.
17. Fortes C, Forastiere F, Farchi S, Mallone S, Trequattrinni T, Anatra F, Schmid G and Perucci CA: The protective effect of the Mediterranean diet on lung cancer. Nutr Cancer 46: 30-37, 2003.
18. Bosetti C, Negri E, Franceschi S, Talamini R, Montella M, Conti E, Lagiou P, Parazzini F and La Vecchia C: Olive oil, seed oils and other added fats in relation to ovarian cancer (Italy). Cancer Causes Control 13: 465-470, 2002.
19. Monti MC, Margarucci L, Tosco A, Riccio R and Casapullo A: New insights on the interaction mechanism between tau protein and oleocanthal, an extra-virgin olive-oil bioactive component. Food Funct 2: 423-428, 2011.
20. Monti MC, Margarucci L, Riccio R and Casapullo A: Modulation of tau protein fibrillization by oleocanthal. J Nat Prod 75: 1584-1588, 2012.
21. Lucas L, Russell A and Keast R: Molecular mechanisms of inflammation. Anti-inflammatory benefits of virgin olive oil and the phenolic compound oleocanthal. Curr Pharm Des 17: 754-768, 2011.
22. Cicerale S, Breslin PA, Beauchamp GK and Keast RS: Sensory characterization of the irritant properties of oleocanthal, a natural anti-inflammatory agent in extra virgin olive oils. Chem Senses 34: 333-339, 2009.
23. Romero C, Medina E, Vargas J, Brenes M and De Castro A: In vitro activity of olive oil polyphenols against Helicobacter pylori. J Agric Food Chem 55: 680-686, 2007.
24. Busnena BA, Foudah AI, Melancon T and El Sayed KA: Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer. Bioorg Med Chem 21: 2117-2127, 2013.
25. Akl MR, Ayoub NM, Mohyeldin MM, Busnena BA, Foudah AI, Liu YY and Sayed KA: Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. PLoS One 9: e97622, 2014.
26. Elnagar AY, Sylvester PW and El Sayed KA: (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers. Planta Med 77: 1013-1019, 2011.
27. Scotece M, Gómez R, Conde J, Lopez V, Gómez-Reino JJ, Lago F, Smith AB III and Gualillo O: Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells. Curr Med Chem 20: 2467-2475, 2013.
28. Pei T, Meng Q, Han J, Li HS, Song R, Sun B, Pan S, Liang D and Liu L: (-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma. Oncotarget: Jun 2, 2016 (Epub ahead of print).
29. Smith AB III, Han Q, Breslin PA and Beauchamp GK: Synthesis and assignment of absolute configuration of (-)-oleocanthal: A potent, naturally occurring non-steroidal anti-inflammatory and anti-oxidant agent derived from extra virgin olive oils. Org Lett 7: 5075-5078, 2005.
30. Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, Wang J, Lu Z, Song X, Pei T, et al: Reciprocal activation between ATPase inhibitory factor 1 and NF-κB drives hepatocellular carcinoma angiogenesis and metastasis. Hepatology 60: 1659-1673, 2014.
31. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005.
32. Al Zaid Siddiquee K and Turkson J: STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18: 254-267, 2008.
33. Fan TP, Yeh JC, Leung KW, Yue PY and Wong RN: Angiogenesis: From plants to blood vessels. Trends Pharmacol Sci 27: 297-309, 2006.
34. Tournaire R, Simon MP, le Noble F, Eichmann A, England P and Pouysségur J: A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep 5: 262-267, 2004.
35. Hartman ML and Czyz M: Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett 331: 24-34, 2013.
36. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF and Hersey P: Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 20: 416-426, 2007.
37. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R and Yu H: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21: 7001-7010, 2002.
38. Ascierto PA, Leonardi E, Ottaiano A, Napolitano M, Scala S and Castello G: Prognostic value of serum VEGF in melanoma patients: A pilot study. Anticancer Res 24: 4255-4258, 2004.
39. Rotte A, Martinka M and Li G: MMP2 expression is a prognostic marker for primary melanoma patients. Cell Oncol (Dordr) 35: 207-216, 2012.
40. Nikkola J1, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM and Pyrhönen S: High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11: 5158-5166, 2005.
41. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R and Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23: 3550-3560, 2004.